Bard Pharmaceuticals

What Bard Pharmaceuticals does

Bard Pharmaceuticals, operating under the legal name Mundipharma International Limited, is a privately held UK-based pharmaceutical company headquartered in Cambridge, founded in 1966 with 251-500 employees. The company manufactures and distributes pharmaceutical medicines across multiple therapeutic areas through a global network of regional country operations, with country-specific adaptations for indications, presentations, and prescribing information. Its go-to-market combines direct field sales to healthcare professionals — supported by a dedicated HCP portal (mundipharmapro.com) — with regional distributor and wholesale channels serving global markets. The company also maintains a Consumer Health segment alongside its core prescription pharmaceutical business.

The company's stated mission centers on patient-centric healthcare, with operational emphasis on access to medicines for unmet medical needs and ESG commitments. It serves two primary personas: end-use patients who rely on its medicines, and healthcare professionals who prescribe and administer them. Digital presence is built around a corporate website featuring therapeutic area overviews, ESG thought leadership, and patient-centric storytelling, supplemented by social media amplification. No specific product names, pricing structures, patent portfolio, management team details, or financial performance metrics are disclosed in the available source material, which materially limits deeper diligence.

Name

Bard Pharmaceuticals

Legal name

Mundipharma International Limited

Website

https://bardpharmaceuticals.co.uk

Company type

Private

Founded year

1966

Operating status

Operating

Headcount range

251–500 employees

Short description

Bard Pharmaceuticals (Mundipharma International Limited) is a private UK-based pharmaceutical manufacturer founded in 1966, distributing medicines across multiple therapeutic areas globally to patients and healthcare professionals through regional country operations and direct HCP sales channels.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

akta.pro secondary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical manufacturing
• Healthcare products
• Patient-centric medicines
• Therapeutic area products
• Prescription medicines

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Core offering

Bard Pharmaceuticals is a UK-based pharmaceutical manufacturer (Cambridge) operating in the healthcare products manufacturing space. The company produces medicines across multiple therapeutic areas with a stated patient-centric operating model. The detailed source material does not enumerate specific named product brands for Bard Pharmaceuticals; it instead describes a global pharmaceutical manufacturing and distribution operation focused on patient outcomes and unmet medical needs.

Product overview

The source data provided pertains to Mundipharma International Limited, not Bard Pharmaceuticals. The Mundipharma website describes a pharmaceutical company focused on patient-centric care across therapeutic areas, with operations in consumer health. However, no specific product names, pharmaceutical brands, or detailed product/service information for Bard Pharmaceuticals is present in this source content.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical medicines (multi-therapeutic area portfolio)

Segments1 record

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights5 records

Direct peers

• Grünenthal GmbH: Private, family-owned European pharmaceutical company with similar mid-size footprint across pain and specialty therapeutic areas, comparable global distribution model, and analogous patient-centric positioning.
• Purdue Pharma: Privately held specialty pharmaceutical company with a portfolio of branded and generic medicines across multiple therapeutic areas, distributed globally through healthcare professional channels.
• Almirall S.A. European specialty pharmaceutical company focused on dermatology and other therapeutic areas, with a similar mid-cap, multi-country commercial footprint.
• H. Lundbeck A/S: Specialty pharmaceutical company with a focused CNS and specialty therapeutic portfolio, comparable in size and global distribution model to a mid-size European pharma manufacturer.
• Stada Arzneimittel AG: European-headquartered private pharma manufacturer with a mix of specialty pharmaceuticals and consumer health products, distributed through similar regional adaptation and wholesaler models.
• Ipsen S.A. European specialty pharmaceutical company with branded prescription products across several therapeutic areas and a global commercial network through healthcare professional channels.
• Recordati S.p.A. Mid-size European specialty pharmaceutical group with diversified therapeutic-area portfolio and a dedicated consumer health segment, mirroring the company's mixed Rx/OTC model.

Broad incumbents

• AstraZeneca: UK-headquartered broad incumbent with extensive therapeutic-area portfolio and global distribution, providing a competitive benchmark for UK-based pharmaceutical operations at much larger scale.
• Teva Pharmaceutical Industries: Large global pharmaceutical manufacturer with both specialty and generics portfolios distributed through professional and wholesaler channels, anchoring the broader competitive set in which mid-size European pharma operate.
• GlaxoSmithKline: UK-headquartered broad incumbent with both prescription pharmaceuticals and a sizable consumer healthcare business, illustrating the dual Rx/OTC structure that the subject company also operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bard Pharmaceuticals